Access to Additional Technology. If BP or Verenium or any of their respective Affiliates Control rights to any Biological Materials, Patent Rights or Technical Information, other than the BP Background Technology or the Verenium Background Technology, as applicable, that would be useful in designing, constructing and operating Plants, BP or Verenium may offer SPE a non-exclusive, worldwide license and sublicense to such Biological Materials, Patent Rights and/or Technical Information for the purpose of granting rights to the SPE Technology Package to Project Companies to use the SPE Technology Package in the Field to design, construct, operate and maintain Plants using the Process and to offer for sale, sell, import or use the ethanol produced by the Process in the Plants, on commercially reasonable terms to be agreed in writing by SPE and BP or Verenium, as applicable.
Access to Additional Technology. (a) If, after the Effective Date and during the Collaboration Term, ISIS comes to own, or acquires a license with the right to grant sublicenses thereunder, any new or additional ISIS Core Technology Patent Rights or Manufacturing Patent Rights, and ATL desires access to such rights, any licenses or sublicenses from ISIS to ATL under such Patents pursuant to Sections 4.1 and 4.2 are conditioned on ATL's agreement (i) to pay, on a flow-through basis, any royalties, milestones or other financial obligations owed to ISIS' licensor arising from a license or sublicense grant to ATL and the practice under such license or sublicense by ATL, its Affiliates or Sublicensees; and (ii) to abide by all terms of the agreement under which a Third Party license is granted to ISIS.
Access to Additional Technology. If, after the Effective Date and during the Term of this Agreement, ISIS creates, develops, comes to own, or acquires a license with the right to grant sublicenses thereunder, any new or additional ISIS Core Technology Patent Rights or Manufacturing Patent Rights, or any new or additional Technology that both (i) is necessary or useful for the development, manufacture or commercialization of VLA4 Compounds/Products and (ii) is or has been [***] and TEVA desires access to any of the foregoing rights for the purpose of development, manufacture or commercialization of VLA4 Compounds/Products, ISIS agrees to negotiate in good faith with ATL and TEVA regarding such access, provided that any licenses or sublicenses from ISIS to ATL or TEVA under such Patents and/or Technology are conditioned on ATL’s or TEVA’s (as applicable) agreement (a) to [***]; and (b) to abide by all terms of the agreement under which a third party license is granted to ISIS. Notwithstanding the foregoing, ISIS agrees to provide to TEVA, [***], (i) any [***] that are used in ISIS’ [***], and/or (ii) such ISIS technology that (A) is required for TEVA to be able to [***] and (B) ISIS is [***] for such required technology.
Access to Additional Technology. (a) If, after the Effective Date and during the Collaboration Term, ISIS comes to own, or acquires a license with the right to grant sublicenses thereunder, any new or additional ISIS Core Technology Patent Rights or Manufacturing Patent Rights, and ATL desires access to such rights, ISIS agrees to negotiate in good faith with ATL regarding such access, provided that any licenses or sublicenses from ISIS to ATL under such Patents pursuant to Sections 4.1 and 4.2 are conditioned on ATL’s agreement (i) to pay, on a flow-through basis, any royalties, milestones or other financial obligations owed to ISIS’ licensor arising from a license or sublicense grant to ATL and the practice under such license or sublicense by ATL, its Affiliates or Sublicensees; and (ii) to abide by all terms of the agreement under which a Third Party license is granted to ISIS.
